DexCom CEO Takes Temporary Medical Leave, Interim Appointments Made

Details

Sayer, is taking a temporary medical leave of absence. In his absence, Jacob S. Leach, the President and Chief Operating Officer, has been appointed as the interim principal executive officer. Additionally, Mark Foletta, the Lead Independent Director, has been appointed as the interim chairman of the Board. Both Leach and Foletta will not receive any additional compensation for their interim roles. Biographical information for Leach is available in Dexcom's definitive proxy statement on Schedule 14A filed on March 27, 2025.

Items reported

About Dexcom Inc.

Dexcom Inc. is a prominent player in the medical technology sector, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The company's primary function is to develop and distribute innovative CGM devices that provide real-time glucose readings, allowing individuals with diabetes to make informed decisions about their health. Dexcom’s products play a critical role in healthcare by offering an alternative to traditional fingerstick testing, thus improving quality of life for many users. The company impacts several sectors, most notably within healthcare and technology, by integrating advanced data analytics and wireless technology into its monitoring systems. This not only aids individuals in managing their glucose levels but also supports healthcare providers in delivering better patient care through data-driven insights. In the financial market, Dexcom Inc. is recognized for its contributions to the growing field of digital health solutions. The company has established itself as a leader in its niche, continuously pushing the boundaries of technology to offer more precise and user-friendly glucose monitoring options. Founded in 1999 and headquartered in San Diego, California, Dexcom remains at the forefront of diabetes management solutions.